Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers

Neuroendocrinology Letters

Volumn 31, Issue 5, 2010, Pages 645-656

  Fišar, Zdeněk ^a   Hroudová, Jana ^a   Raboch, Jiří ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Antidepressive agents; Monoamine oxidase inhibitors; Mood stabilizers

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLORGYLINE; COCAINE; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; IPRONIAZID; LITHIUM; MIRTAZAPINE; MITOCHONDRIAL ENZYME; MOCLOBEMIDE; MOOD STABILIZER; OLANZAPINE; PARGYLINE; PHENETHYLAMINE; REBOXETINE; SEROTONIN; TIANEPTINE; VALPROIC ACID; VENLAFAXINE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN MITOCHONDRION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME ISOLATION; ENZYME KINETICS; ENZYME SUBSTRATE; IN VITRO STUDY; ISOTOPE LABELING; NEUROTRANSMISSION; NONHUMAN; SWINE;

EID: 79651473280     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. Akaike H (1974). A new look at the statistical model identification. IEEE Transactions on Automatic Control. 19: 716-723.
2. Bach AWJ, Lan NC, Johnson DL, Abell CW, Bembenek ME, Kwan S-W, et al (1988). cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc Natl Acad Sci USA. 85: 4934-4938.
3. Baker GB, Urichuk LJ, McKenna KF, Kennedy SH (1999). Metabolism of monoamine oxidase inhibitors. Cell Mol Neurobiol. 19: 411-426. (Pubitemid 29205394)
4. Bonnet U (2003). Moclobemide: therapeutic use and clinical studies. CNS Drug Rev. 9: 97-140.
5. Burkard WP, Da Prada M, Keller HH, Kettler R, Haefely W (1989). Pre-clinical pharmacology of moclobemide. A review of published studies. Br J Psychiatry. 154(Suppl 6): 84-88. (Pubitemid 19282144)
6. Caccia S, Cappi M, Fracasso C, Garattini S (1990). Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. Psychopharmacology (Berl). 100: 509-514. (Pubitemid 20102360)
7. Cesura AM, Kettler R, Imhof R, Da Prada M (1992). Mode of action and characteristics of monoamine oxidase-A inhibition by moclobemide. Psychopharmacology (Berl). 106(Suppl 1): S15-S16.
8. Chen ML, Chen CH (2007). Chronic antipsychotics treatment regulates MAOA, MAOB and COMT gene expression in rat frontal cortex. J Psychiatr Res. 41: 57-62.
9. Chen K, Wu HF, Shih JC (1993). The deduced amino acid sequences of human platelet and frontal cortex monoamine oxidase B are identical. J Neurochem. 61: 187-190. (Pubitemid 23175900)
10. 50) of an enzymatic reaction. Biochem Pharmacol. 22: 3099-3108.
11. Da Prada M, Kettler R, Keller HH, Burkard WP, Muggli-Maniglio D, Haefely WE (1989). Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther. 248: 400-414. (Pubitemid 19063520)
12. Da Prada M, Kettler R, Keller HH, Cesura AM, Richards JG, Saura Marti J, et al (1990). From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors. J Neural Transm Suppl. 29: 279-292.
13. Davidson J, Mcleod MN, Linnoila M, Kurland AA, White HL (1978). Platelet MAO inhibition following tricyclic antidepressant therapy. Am J Psychiatry. 135: 603-605. (Pubitemid 8329040)
14. Edmondson DE, Binda C, Wang J, Upadhyay AK, Mattevi A (2009). Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases. Biochemistry. 48: 4220-4230.
15. Edwards DJ, Burns MO (1974). Effects of tricyclic antidepressants upon human platelet monoamine oxidase. Life Sci. 15: 2045-2058.
16. Egashira T, Kuroiwa Y, Kamijo K (1978). Multiple catalytic sites of rat brain mitochondrial monoamine oxidase. Arch Biochem Biophys. 191: 714-718. (Pubitemid 9077300)
17. Egashira T, Takayama F, Yamanaka Y (1996). Effects of long-term treatment with dicyclic, tricyclic, tetracyclic, and noncyclic antidepressant drugs on monoamine oxidase activity in mouse brain. Gen Pharmacol. 27: 773-778. (Pubitemid 26295633)
18. Egashira T, Takayama F, Yamanaka Y (1999). The inhibition of monoamine oxidase activity by various antidepressants: differences found in various mammalian species. Jpn J Pharmacol. 81: 115-121. (Pubitemid 29479063)
19. Ekstedt B (1976). Substrate specificity of the different forms of monoamine oxidase in rat liver mitochondria. Biochem Pharmacol. 25: 1133-1138.
20. Fagervall I, Ross SB (1986). Inhibition of monoamine oxidase in monoaminergic neurones in the rat brain by irreversible inhibitors. Biochem Pharmacol. 35: 1381-1387. (Pubitemid 16037049)
21. Fišar Z, Krulík R, Fuksová K, Sikora J (1996). Imipramine distribution among red blood cells, plasma and brain tissue. Gen Physiol Biophys. 15: 51-64. (Pubitemid 26175383)
22. Fišar Z, Fuksová K, Sikora J, Kališová L, Velenovská M, Novotná M (2006). Distribution of antidepressants between plasma and red blood cells. Neuroendocrinol Lett. 27: 307-313.
23. Fišar Z, Raboch J (2008). Depression, antidepressants, and peripheral blood components. Neuroendocrinol Lett. 29: 17-28.
24. Fišar Z, Hroudová J (2010). Intracellular signalling pathways and mood disorders. Folia Biol. 56: 135-148.
25. Fowler CJ, Tipton KF (1981). Concentration dependence of the oxidation of tyramine by the two forms of rat liver mitochondrial monoamine oxidase. Biochem Pharmacol. 30: 3329-3332. (Pubitemid 12248338)
26. Fowler PW, Balali-Mood K, Deol S, Coveney PV, Sansom MS (2007). Monotopic enzymes and lipid bilayers: a comparative study. Biochemistry. 46: 3108-3115. (Pubitemid 46449133)
27. Gnerre C, Kosel M, Baumann P, Carrupt P-A, Testa B (2001). Interaction of psychotropic drugs with monoamine oxidase in rat brain. J Pharm Pharmacol. 53: 1125-1130. (Pubitemid 32754943)
28. Gómez N, Balsa D, Unzeta M (1988). A comparative study of some kinetic and molecular properties of microsomal and mitochondrial monoamine oxidase. Biochem Pharmacol. 37: 3407-3413.
29. Green AL, McGachy HA (1987). The inhibition of monoamine oxidase by tricyclic antidepressants: the influence of the nature of the substrate and the source of the enzyme. J Pharm Pharmacol. 39: 392-394. (Pubitemid 17119499)
30. Green AL, O'Grady JE, Vass M (1989). The effect of some tricyclic antidepressants on the inhibition of mouse brain monoamine oxidase in-vivo by phenelzine. J Pharm Pharmacol. 41: 50-51. (Pubitemid 19043923)
31. Guentert TW, Banken L, Hilton S, Holford NH (1995). Moclobemide: relationships between dose, drug concentration in plasma, and occurrence of adverse events. J Clin Psychopharmacol. 15(Suppl 2): 84S-94S.
32. Haddjeri N, Szabo ST, de Montigny C, Blier P (2000). Increased tonic activation of rat forebrain 5-HT(1A) receptors by lithium addition to antidepressant treatments. Neuropsychopharmacology. 22: 346-356. (Pubitemid 30105763)
33. Haefely W, Burkard WP, Cesura AM, Kettler R, Lorez HP, Martin JR, et al (1992). Biochemistry and pharmacology of moclobemide, a prototype RIMA. Psychopharmacology (Berl). 106(Suppl 1): S6-S14.
34. Haefely W, Burkard WP, Cesura A, Colzi A, Kettler R, Lorez HP, et al (1993). Pharmacology of moclobemide. Clin Neuropharmacol. 16(Suppl 2): S8-S18. (Pubitemid 23341460)
35. Hindmarch I (2002). Beyond the monoamine hypothesis: mechanisms, molecules and methods. Eur Psychiatry. 17(Suppl 3): 294-299.
36. Holford NH, Guentert TW, Dingemanse J, Banken L (1994). Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor. Br J Clin Pharmacol. 37: 433-439. (Pubitemid 24197136)
37. Honecker H, Christ W, Müller-Oerlinghausen B, Coper H (1976). Critical evaluation of measurement of platelet monoamine oxidase in man. J Clin Chem Clin Biochem. 14: 453-458.
38. Horstink M, Tolosa E, Bonuccelli U, Deuschl G, Friedman A, Kanovsky P, et al; European Federation of Neurological Societies; Movement Disorder Society-European Section (2006). Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol. 13: 1170-1185.
39. Huang RH, Faulkner R (1981). The role of phospholipid in the multiple functional forms of brain monoamine oxidase. J Biol Chem. 256: 9211-9215. (Pubitemid 12208313)
40. Iwersen S, Schmoldt A (1996). Three suicide attempts with moclobemide. J Toxicol Clin Toxicol. 34: 223-225.
41. Jauch R, Griesser E, Oesterhelt G, Arnold W, Meister W, Ziegler WH, et al (1990). Biotransformation of moclobemide in humans. Acta Psychiatr Scand. 82(Suppl 360): 87-90. (Pubitemid 20320308)
42. Karson CN, Newton JE, Livingston R, Jolly JB, Cooper TB, Sprigg J, et al (1993). Human brain fluoxetine concentrations. J Neuropsychiatry Clin Neurosci. 5: 322-329. (Pubitemid 23234402)
43. Kessler RC, Angermeyer M, Anthony JC, DE Graaf R, Demyttenaere K, Gasquet I, et al (2007). Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization's World Mental Health Survey Initiative. World Psychiatry. 6: 168-176. (Pubitemid 350047829)
44. Kettler R, Da Prada M, Burkard WP (1990). Comparison of monoamine oxidase-A inhibition by moclobemide in vitro and ex vivo in rats. Acta Psychiatr Scand. 82(Suppl 360): 101-102. (Pubitemid 20320312)
45. Kitaichi Y, Inoue T, Nakagawa S, Izumi T, Koyama T (2006). Effect of co-administration of subchronic lithium pretreatment and acute MAO inhibitors on extracellular monoamine levels and the expression of contextual conditioned fear in rats. Eur J Pharmacol. 532: 236-245.
46. Lecrubier Y, Guelfi JD (1990). Efficacy of reversible inhibitors of monoamine oxidase-Á in various forms of depression. Acta Psychiatr Scand. 82(Suppl 360): 18-23. (Pubitemid 20320283)
47. Lecrubier Y (1994). Risk-benefit assessment of newer versus older monoamine oxidase (MAO) inhibitors. Drug Saf. 10: 292-300.
48. Lotufo-Neto F, Trivedi M, Thase ME (1999). Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology. 20: 226-247. (Pubitemid 29067402)
49. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951). Protein measurement with the Folin phenol reagent. J Biol Chem. 193: 265-275.
50. Magder DM, Aleksic I, Kennedy SH (2000). Tolerability and efficacy of high-dose moclobemide alone and in combination with lithium and trazodone. J Clin Psychopharmacol. 20: 394-395. (Pubitemid 30318378)
51. Meyer JH, Ginovart N, Boovariwala A, Sagrati S, Hussey D, Garcia A et al (2006). Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry. 63: 1209-1216. (Pubitemid 44708079)
52. Mukherjee J, Yang Z-Y (1997). Evaluation of monoamine oxidase B inhibition by fluoxetine (Prozac): an in vitro and in vivo study. Eur J Pharmacol. 337: 111-114. (Pubitemid 27468868)
53. Mukherjee J, Yang Z-Y (1999). Monoamine oxidase A inhibition by fluoxetine: an in vitro and in vivo study. Synapse. 31: 285-289. (Pubitemid 29070289)
54. Muraki I, Inoue T, Hashimoto S, Izumi T, Ito K, Koyama T (2001). Effect of subchronic lithium treatment on citalopram-induced increases in extracellular concentrations of serotonin in the medial prefrontal cortex. J Neurochem. 76: 490-497. (Pubitemid 32097026)
55. Muriel P, Pérez-Rojas JM (2003). Nitric oxide inhibits mitochondrial monoamine oxidase activity and decreases outer mitochondria membrane fluidity. Comp Biochem Physiol C Toxicol Pharmacol. 136: 191-197. (Pubitemid 37500848)
56. Nag M (2004). Effect of chlorpromazine, imipramine and lithium on MAO-A and MAO-B activity in rat brain mitochondria. Indian J Exp Biol. 42: 941-944.
57. Nair NPV, Ahmed SK, Kin NMK (1993). Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide. J Psychiatr Neurosci. 18: 214-225. (Pubitemid 24018028)
58. Nelson JC (1999). A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression. Biol Psychiatry. 46: 1301-1308.
59. 3 augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry. 163: 1519-1530. (Pubitemid 44465751)
60. 2-imidazoline receptors in rat liver. Br J Pharmacol. 121: 901-912. (Pubitemid 27277783)
61. Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC (2007). Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry. 62: 1217-1227. (Pubitemid 350060895)
62. Praško J, Dockery C, Horáček J, Houbová P, Kosová J, Klaschka J, et al (2006). Moclobemide and cognitive behavioral therapy in the treatment of social phobia. A six-month controlled study and 24 months follow up. Neuroendocrinol Lett. 27: 473-481.
63. Ramsay RR, Gravestock MB (2003). Monoamine oxidases: to inhibit or not to inhibit. Mini Rev Med Chem. 3: 129-136.
64. Redrobe JP, Bourin M (1999). Evidence of the activity of lithium on 5-HT1B receptors in the mouse forced swimming test: comparison with carbamazepine and sodium valproate. Psychopharmacology (Berl). 141: 370-377. (Pubitemid 29190005)
65. Reid AA, Hill JL, Murphy DL (1988). Interactions of tricyclic antidepressant drugs with human and rat monoamine oxidase type B. Naunyn Schmiedebergs Arch Pharmacol. 338: 678-83. (Pubitemid 19030097)
66. Reveley MA, Glover V, Slander M, Coppen A (1979). Absence of platelet monamine oxidase inhibition during amitriptyline or zimelidine treatment. Br J Clin Pharmacol. 8: 375-378. (Pubitemid 10229595)
67. Reveley MA, Glover V, Sandler M, Coppen A (1981). Increased platelet monoamine oxidase activity in affective disorders. Psychopharmacology (Berl). 73: 257-260. (Pubitemid 11104041)
68. Reyes E, Lisansky J (1984). Effects of tricyclic antidepressants on platelet monoamine oxidase activity. Clin Pharmacol Ther. 35: 531-534. (Pubitemid 14133495)
69. Riederer P, Danielczyk W, Grünblatt E (2004). Monoamine oxidase-B inhibition in Alzheimer's disease. NeuroToxicology. 25: 271-277. (Pubitemid 38044188)
70. Roth JA, Gillis CN (1974). Inhibition of lung, liver and brain monoamine oxidase by imipramine and desipramine. Biochem Pharmacol. 23: 1138-1140.
71. Smith TE, Weisssbach H, Udenfriend S (1963). Studies on monoamine oxidase: the mechanism of inhibition of monoamine oxidase by iproniazid. Biochemistry. 2: 746-751.
72. Sullivan JL, Dackis C, Stanfield C (1977). In vivo inhibition of platelet MAO activity by tricyclic antidepressants. Am J Psychiatry. 134: 188-190.
73. Sullivan JL, Zung WW, Stanfield CN, Cavenar JO Jr (1978). Clinical correlates of tricyclic antidepressant-mediated inhibition of platelet monoamine oxidase. Biol Psychiatry. 13: 399-407. (Pubitemid 8359223)
74. Stahl SM, Felker A (2008). Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr. 13: 855-870.
75. Ulus IH, Maher TJ, Wurtman RJ (2000). Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochem Pharmacol. 59: 1611-1621. (Pubitemid 30229896)
76. Whittaker VP (1969). The synaptosome. In: Lajtha A, editor. Handbook of Neurochemistry. Vol. II Structural Neurochemistry. New York, London: Plenum Press. p. 327-364.
77. Youdim MB, Bakhle YS (2006). Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol. 147(Suppl 1): S287-S296. (Pubitemid 43077287)
78. Youdim MB, Edmondson D, Tipton KF (2006). The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci. 7: 295-309.